运动作为改善非小细胞肺癌免疫治疗反应的工具 (ImmuEX)
研究概览
详细说明
肺癌是全球癌症相关死亡的首要原因。 几十年前,肺癌首次诊断时的预后通常较差,中位生存期仅有数月。 新型免疫治疗方案显著提高了生存时间——尤其是在某些组织学和分子病理学亚型中。 运动对结直肠癌或乳腺癌等多种癌症发病率的积极影响先前已得到证实。 与久坐人群相比,身体活跃者被诊断出癌症的频率显著降低。 在肿瘤随访护理中,运动和训练的积极影响及其对生存优势的益处也已得到验证,例如在乳腺癌患者中。
此外,现有数据显示运动对免疫系统有积极影响:活跃个体血清中的促炎标志物呈现不同模式,每次运动都会产生免疫刺激效应,即使在静息状态下也会改变免疫血清谱。 因此,定期运动具有抗炎长期效应。
假设与目标:通过本项目,我们旨在证明在医学指导的训练方案下可能对免疫治疗反应产生的益处。
设置与方法。 为在此背景下准确定义“运动”,作为第一步,我们将在健康个体中测试两种运动类型。 根据通过肺功能运动试验确定的个体运动能力,健康受试者将进行中等强度持续运动(MICE)或高强度间歇训练(HIIT)。 通过训练前后的静脉采血,我们将确定运动引起的血清免疫标志物的相应变化。 随后,接受免疫治疗的肺癌患者将进行相同的两种训练类型,一组患者进行MICE训练,一组进行HIIT训练,第三组将接受一般运动建议。 我们将比较各组之间的治疗反应和炎症血清参数。 运动患者将被建议每周在医疗监督下训练一次,并额外每周每天快走30分钟。 我们的假设是,运动应作为补充治疗策略应用于所有肿瘤治疗场景,可能不仅改善身体健康和福祉,还能提高治疗反应。 除了通过更好的身体能力和健康改善患者生活质量、帮助其日常活动外,我们提出未来在各种肿瘤场景中实施运动计划可能改善患者的预后。
科学新颖性。 现有文献中肿瘤场景下运动方案的标准化通常较差。 我们开展的研究是为数不多的明确界定两组运动类型、持续时间、时机和强度的研究之一,分别将两种不同训练类型与久坐对照组患者进行比较。 运动需被视为一种药物,与任何药物一样,必须明确界定最佳剂量。 此外,我们将在研究中实施启动运动,即患者在免疫治疗给药前后进行运动,假设这可能进一步改善治疗反应。
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Lukas Spielbüchler, MEd, BEd
- 电话号码:+43 699 10558825
- 邮箱:lukas.spielbuechler@medunigraz.at
研究联系人备份
- 姓名:Emine Betül Deniz, MSc
- 电话号码:+43 676 4029105
- 邮箱:emine.deniz@medunigraz.at
学习地点
-
-
-
Graz、奥地利、8010
- 招聘中
- Medical University of Graz
-
接触:
- Elisabeth Taucher, Dr. Dr.
- 电话号码:+43 6648438876
- 邮箱:elisabeth.taucher@medunigraz.at
-
接触:
- Nikolaus Kneidinger, Prof. Dr.
- 电话号码:+43 316 385 12183
- 邮箱:nikolaus.kneidinger@medunigraz.at
-
首席研究员:
- Elisabeth Taucher, Dr. Dr.
-
首席研究员:
- Nikolaus Kneidinger, Prof. Dr.
-
副研究员:
- Lukas Spielbüchler, BEd, MEd
-
副研究员:
- Emine Betül Deniz, MSc
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
纳入标准:首次诊断为任何组织学亚型的非小细胞肺癌患者,接受包含免疫疗法(伴或不伴化疗)的治疗方案。
-
排除标准:
- 恶病质(BMI<18.5)
- 不稳定的骨转移
- 骨科状况导致患者无法使用固定自行车
- 任何运动训练的医学禁忌症
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:持续运动
该组的患者将接受为期12周的训练治疗方案,包括每周两次受监督的中等强度持续运动(MICE),以及每周五次、每次30分钟的家庭步行运动。
|
一项进行持续性运动的研究组将与一项进行高强度间歇性运动的研究组,在为期12周的疗程中分别进行比较。
两组都将与久坐不动的对照组患者进行比较。
其他名称:
|
|
实验性的:高强度间歇运动
该组患者将接受为期12周的训练治疗方案,包括每周两次监督下的高强度间歇运动,以及每周五次、每次30分钟的家庭步行运动。
|
一项进行持续性运动的研究组将与一项进行高强度间歇性运动的研究组,在为期12周的疗程中分别进行比较。
两组都将与久坐不动的对照组患者进行比较。
其他名称:
|
|
有源比较器:控制
该组的患者将收到关于积极生活方式的一般建议,但不会参加监督训练课程,也不会被要求进行居家锻炼。
|
对于对照组患者,将提供一般运动建议(例如,适合所有成年个体的CDC建议),但不会进行训练治疗干预,也不需要居家步行锻炼。
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
FACS analysis of PBMCs
大体时间:Before and after the 12 week training therapy intervention, i.e. differences seen between 12 and 14 weeks
|
The FACS panel comprises: CD4pos Helper T Cells, CD8pos Cytotoxic T Cells, Regulatory T Cells, Effector Memory T Cells, Naive/Memory Subsets, Activated/Exhausted T Cells, gamma-delta T Cells, Naive B Cells, Memory B Cells, Transitional B Cells, Classical Monocytes, Intermediate Monocytes, Non Classical Monocytes, NK CD16pos, NK CD16neg, Neutrophils, Basophils, Mast Cells, Viable vs. Dead Cells, Immune Checkpoint Subsets, Activation/Proliferation Markers. The total numbers and percentages of cells positive for the above listed markers are the primary outcome measures. The surface marker profile of PBMCs as a whole will define the outcome, showing differences between exercising and sedentary patients, e.g.: "In patients from the exercise group, XX% of naive B cells were found, and XX% of CD4pos Helper T Cells, and XX% CD8pos Cytotoxic T Cells were found. In patients from the control group, the proportion of naive B cells was XX...". |
Before and after the 12 week training therapy intervention, i.e. differences seen between 12 and 14 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Cytokine analysis from peripheral blood sampling
大体时间:From enrollment to after the 12 week intervention, i.e. a period between 12-14 weeks
|
IFN gamma, IL-13, GM-CSF, IL-1β, IL-5, sCD25 (IL-2Ra), IL-4, VEGF, IL-17A, IL-18, CCL4 (MIP-1β), IL-15, IL-12p70. The count of the above listed cytokines in pg/ml will be recorded in venous blood samples, with higher values after exercise indicating a more pronounced inflammatory response. Blood plasma samples from the patients will be collected at the beginning and after the 12 weeks exercise intervention for cytokine testing. Additionally, cytokine profiling will be done before and after one exercise bout to illustrate acute changes. Multiplex detecton kits (Legendplex) will be used for cytokine profiling. For every cytokine, differences will be recorded in one patient at enrollment and after completion of the 12 week training therapy. Differences between the exercising and non-exercising patients will be recorded as well. E.g. "IFNgamma levels were on average XX pg/ml before the intervention. After the intervention period of 12 weeks, IFNgamma levels were on average XX pg/ml." |
From enrollment to after the 12 week intervention, i.e. a period between 12-14 weeks
|
|
Number of participants with changes in mitochondrial function (Seahorse analysis)
大体时间:From enrollment to after completion of the exercise intervention, i.e. a period between 12-14 weeks
|
Mitochondrial function parameters are combined to assess how well mitochondria work in a given patient. Oxygen Consumption Rate (OCR), Extracellular Acidification Rate (ECAR), Glycolytic Rate, Glycolytic Capacity, Basal Oxygen Consumption Rate, Maximal Respiration, and Spare Respiratory Rapacity are assessed by means of a Seahorse assay using a Seahorse XF Analyzer from Agilent, that measures the real-time metabolic activity of live cells by simultaneously assessing mitochondrial respiration and glycolysis. The number of patients with changes in oxygen consumption rate (OCR), which indicates mitochondrial respiration, and the extracellular acidification rate (ECAR), which is linked to glycolysis, is analysed. Aberrations in mitochondrial function as well as changes from before to after the intervention in % of patients / total number of patients is assessed. |
From enrollment to after completion of the exercise intervention, i.e. a period between 12-14 weeks
|
|
Mass spectrometry - Lipidomics
大体时间:From enrollment to after completion of the 12 week exercise intervention, i.e. a time period between 12 and 14 weeks
|
Marker Name (or m/z value), Retention Time and Intensity/Abundance of a given metabolite will be analysed in plasma samples.
Markers comprise H4CH, H4A1, H4A2, TPA1, HDA1, IDPL, H4PL, Glutamine, L5CH, H3CH, TPA2, HDA2, L5PL, HDCH, H3A2, TPCH, L5PN, L5AB, V1FC, H3FC, L5FC, SPC, IDTG, V5FC, Glutamic acid, H4FC, Alanine, HDPL, V2PL, Glucose, LDCH, L4CH, H3A1, L4FC, V2TG.
Lipidomics is used to describe the complete lipid profile within the patients' immune cells.
It is a subset of the "metabolome".
As opposed to classic analysis of carbohydrate metabolism, lipids are more stable, allowing for an analysis of frozen PBMCs.
Our hypothesis is that upon the exercise program, lipidomics of the immune cells significantly change, allowing for a more favorable antitumor immune response.
Total counts of each above-listed metabolite in the blood will be determined, e.g. in milligrams per deciliter and for every metabolite, changes between exercising and sedentary patients are recorded.
|
From enrollment to after completion of the 12 week exercise intervention, i.e. a time period between 12 and 14 weeks
|
|
Aerobic capacity
大体时间:From enrollment to after completion of the 12 week training therapy intervention, i.e. a time period between 12 and 14 weeks
|
With spiroergometry testing at the beginning of the exercise program and after completion of the program at 12 weeks, the investigators will assess potential changes in the patients' aerobic capacity. The normal range for womens' VO2max starts at 30 ml/kg/min and for men at 35 ml/kg/min with lower ranges expected in the usually elderly tumor patients. Improvements over the 12 week intervention period will be recorded. |
From enrollment to after completion of the 12 week training therapy intervention, i.e. a time period between 12 and 14 weeks
|
|
Quality of life - EORTC-QLQ C30 (German version)
大体时间:From enrollment to after completion of the 12 week training therapy intervention, i.e. a period between 12 and 14 weeks
|
The patient's quality of life will be assessed by two questionnaires, one for quality of life in cancer patients in general and one questionnaire specifically for lung cancer. The EORTC-QLQ C30 (German version) has a range from 0-100 with higher values representing a better quality of life. Minimal Important Difference (MID): A change of 5 to 10 points is generally considered clinically meaningful. Differences of 10 points are often used to indicate clinical relevance. |
From enrollment to after completion of the 12 week training therapy intervention, i.e. a period between 12 and 14 weeks
|
|
Quality of life - FACT-L scale (German version)
大体时间:From enrollment to after 12 weeks, i.e. a period between 12 and 14 weeks
|
The FACT-L (Functional Assessment of Cancer Therapy-Lung) questionnaire has a maximum possible total score of 0 to 136, which includes the 27-item FACT-G (general) and the 9-item Lung Cancer Subscale (LCS).
Higher scores indicate better quality of life.
|
From enrollment to after 12 weeks, i.e. a period between 12 and 14 weeks
|
|
Bodycomposition / Bioimpedance measurement
大体时间:Enrollment to after 12 weeks, i.e. a period between 12 and 14 weeks
|
Bioimpedance measurement will be used to determine body composition (and possible increments in muscle mass).
The measures are given in % of total body mass.
Higher values of muscle mass are generally considered better and indicate a good response to training, whist declines in muscle mass are often observed in inactive cancer patients.
|
Enrollment to after 12 weeks, i.e. a period between 12 and 14 weeks
|
合作者和调查者
调查人员
- 首席研究员:Elisabeth Taucher, Dr. Dr.、Medical University of Graz
出版物和有用的链接
一般刊物
- Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, Zucker DS, Matthews CE, Ligibel JA, Gerber LH, Morris GS, Patel AV, Hue TF, Perna FM, Schmitz KH. Exercise Guidelines for Cancer Survivors: Consensus Statement from International Multidisciplinary Roundtable. Med Sci Sports Exerc. 2019 Nov;51(11):2375-2390. doi: 10.1249/MSS.0000000000002116.
- Martin-Ruiz A, Fiuza-Luces C, Rincon-Castanedo C, Fernandez-Moreno D, Galvez BG, Martinez-Martinez E, Martin-Acosta P, Coronado MJ, Franco-Luzon L, Gonzalez-Murillo A, Ramirez M, Provencio M, Lucia A. Benefits of exercise and immunotherapy in a murine model of human non-small-cell lung carcinoma. Exerc Immunol Rev. 2020;26:100-115.
- Ungvari Z, Fekete M, Varga P, Munkacsy G, Fekete JT, Lehoczki A, Buda A, Kiss C, Ungvari A, Gyorffy B. Exercise and survival benefit in cancer patients: evidence from a comprehensive meta-analysis. Geroscience. 2025 Jun;47(3):5235-5255. doi: 10.1007/s11357-025-01647-0. Epub 2025 Apr 12.
- Winters-Stone KM, Neil SE, Campbell KL. Attention to principles of exercise training: a review of exercise studies for survivors of cancers other than breast. Br J Sports Med. 2014 Jun;48(12):987-95. doi: 10.1136/bjsports-2012-091732. Epub 2013 Jan 4.
- Rezende LFM, Sa TH, Markozannes G, Rey-Lopez JP, Lee IM, Tsilidis KK, Ioannidis JPA, Eluf-Neto J. Physical activity and cancer: an umbrella review of the literature including 22 major anatomical sites and 770 000 cancer cases. Br J Sports Med. 2018 Jul;52(13):826-833. doi: 10.1136/bjsports-2017-098391. Epub 2017 Nov 16.
- Ashcraft KA, Peace RM, Betof AS, Dewhirst MW, Jones LW. Efficacy and Mechanisms of Aerobic Exercise on Cancer Initiation, Progression, and Metastasis: A Critical Systematic Review of In Vivo Preclinical Data. Cancer Res. 2016 Jul 15;76(14):4032-50. doi: 10.1158/0008-5472.CAN-16-0887. Epub 2016 Jul 5.
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- ImmuEX
- PAT1625724 (其他标识符:FWF Austrian Science Fund)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
IPD 计划说明
研究数据/文件
-
个人参与者数据集
信息评论:IPD将被收集在REDCap数据库中。 由于患者招募尚未开始,目前尚未录入任何数据。 我们尚未决定未来是否与其他研究人员共享IPD。
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.